Christine S. Lee
YOU?
Author Swipe
View article: JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer Open
CDK4/6 inhibitors in combination with endocrine therapy are now used as front-line treatment for patients with estrogen-receptor positive (ER+) breast cancer. While this combination improves overall survival, the mechanisms of disease prog…
View article: Advancing Health Equity: Efforts to Expand Education on Skin Lightening Products
Advancing Health Equity: Efforts to Expand Education on Skin Lightening Products Open
View article: Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 78KB, Supplementary Figure 2: Deregulation of cyclin E in tamoxifen-resistant cells. MCF-7C and TAMR cells were treated with vehicle, OH-Tam (100 nM) or fulvestrant (10 nM). A: S phase percentage derived from flow cytometry of pr…
View article: Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 41KB, Supplementary Figure 3: Effect of overexpression of cyclins E1 and E2 on antiestrogen-induced growth arrest. T-47D cells overexpressing cyclin E1, cyclin E2 or vector control were treated with fulvestrant or vehicle. Densit…
View article: Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 56KB.
View article: Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 929KB, Supplementary Figure 1: Cyclin E2 association with breast cancer subtype, grade, and outcome. A: Relationship between a second cyclin E2 probeset and breast cancer subtype, or histological grade. Box: upper and lower quart…
View article: Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 929KB, Supplementary Figure 1: Cyclin E2 association with breast cancer subtype, grade, and outcome. A: Relationship between a second cyclin E2 probeset and breast cancer subtype, or histological grade. Box: upper and lower quart…
View article: Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 78KB, Supplementary Figure 2: Deregulation of cyclin E in tamoxifen-resistant cells. MCF-7C and TAMR cells were treated with vehicle, OH-Tam (100 nM) or fulvestrant (10 nM). A: S phase percentage derived from flow cytometry of pr…
View article: Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 56KB.
View article: Data from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Data from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
Cyclin E2, but not cyclin E1, is included in several gene signatures that predict disease progression in either tamoxifen-resistant or metastatic breast cancer. We therefore examined the role of cyclin E2 in antiestrogen resistance in v…
View article: Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 41KB, Supplementary Figure 3: Effect of overexpression of cyclins E1 and E2 on antiestrogen-induced growth arrest. T-47D cells overexpressing cyclin E1, cyclin E2 or vector control were treated with fulvestrant or vehicle. Densit…
View article: Data from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Data from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
Cyclin E2, but not cyclin E1, is included in several gene signatures that predict disease progression in either tamoxifen-resistant or metastatic breast cancer. We therefore examined the role of cyclin E2 in antiestrogen resistance in v…